申请人:BOEHRINGER INGELHEIM INTERNATIONAL GMBH
公开号:US20150368230A1
公开(公告)日:2015-12-24
Novel radiotracer for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging are described. Specifically, the invention relates to
18
F-labeled afatinib suitable as a PET or SPECT tracer for imaging epidermal growth factor receptor (EGFR, erbB1) and human epidermal growth factor receptor 2 (Her2, erbB2), to a precursor compound for use in its synthesis, to methods for the preparation
18
F-labeled afatinib, as well as to the use thereof in in vivo diagnosis, tumor imaging or patient stratification on the basis of mutational status of EGFR (erbB1) and Her2 (erbB2).
本发明描述了用于正电子发射断层扫描(PET)或单光子发射计算机断层扫描(SPECT)成像的新型放射性示踪剂。具体而言,本发明涉及适用于PET或SPECT示踪剂的18F标记的阿法替尼,用于成像表皮生长因子受体(EGFR,erbB1)和人类表皮生长因子受体2(Her2,erbB2),以及用于其合成的前体化合物,制备18F标记的阿法替尼的方法,以及其在体内诊断、肿瘤成像或基于EGFR(erbB1)和Her2(erbB2)突变状态的患者分层的用途。